Eisai And Shionogi Develop Obesity Drug Meridia In Japan
This article was originally published in PharmAsia News
Executive SummaryMajor drug maker Eisai is aiming to launch its obesity drug Meridia (sibutramine) in two to three years. Eisai signed a licensing deal with U.S. major drug maker Abbott Laboratories and obtained exclusive rights to develop and market the drug in Japan. According to Eisai, Japanese domestic clinical trials have shown efficacy in weight loss. The company has submitted an NDA with the Ministry of Health, Labor and Welfare. Shionogi also plans to develop an obesity agent in 10 years. (Click here for more - Japanese language
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.